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Abstract
Background: Tuberculosis and HIV co-infection is one of the main drivers of poor outcome for both diseases in Zambia.
HIV infection has been found to predict TB infection/disease and TB has been reported as a major cause of death among
individuals with HIV. Improving case detection of TB/HIV co-infection has the potential to lead to early treatment of both
conditions and can impact positively on treatment outcomes. This study was conducted in order to determine the HIV
prevalence among adults with tuberculosis in a national prevalence survey setting in Zambia, 2013–2014.
Methods: A countrywide cross sectional survey was conducted in 2013/2014 using stratified cluster sampling, proportional
to population size for rural and urban populations. Each of the 66 countrywide clusters represented one census supervisory
area with cluster size averaging 825 individuals. Socio-demographic characteristics were collected during a household visit
by trained survey staff. A standard symptom-screening questionnaire was administered to 46,099 eligible individuals across
all clusters, followed by chest x-ray reading for all eligible. Those symptomatic or with x-ray abnormalities were confirmed
or ruled out as TB case by either liquid culture or Xpert MTBRif performed at the three central reference laboratories. HIV
testing was offered to all participants at the survey site following the national testing algorithm with rapid tests. The
prevalence was expressed as the proportion of HIV among TB cases with 95% confidence limits.
Results: A total of 265/6123 (4.3%) participants were confirmed of having tuberculosis. Thirty-six of 151 TB survey cases
who accepted HIV testing were HIV-seropositive (23.8%; 95% CI 17.2–31.4). The mean age of the TB/HIV cases was 37.
6 years (range 24–70). The majority of the TB/HIV cases had some chest x-ray abnormality (88.9%); were smear positive
(50.0%), and/or had a positive culture result (94.4%). None of the 36 detected TB/HIV cases were already on TB treatment,
and 5/36 (13.9%) had a previous history of TB treatment. The proportion of TB/HIV was higher in urban than in the rural
clusters. The HIV status was unknown for 114/265 (43.0%) of the TB cases.
Conclusions: The TB/HIV prevalence in the general population was found to be lower than what is routinely reported as
incident TB/HIV cases at facility level. However; the TB/HIV co-infection was higher in areas with higher TB prevalence.
Innovative and effective strategies for ensuring TB/HIV co-infected individuals are detected and treated early are required.
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Background
People living with TB are 26–31 times more likely to be co-
infected with HIV, particularly in sub-Saharan Africa [1–3],
with co-infection rates having been reported as high as 95%
in Southern Africa [4]. The diagnosis of TB remains a chal-
lenge especially in areas where access to health services is
limited and in view of HIV-positivity being associated with
a high rate of extra-pulmonary TB, which offers formidable
diagnostic challenges on its own [5].
In Zambia, the HIV prevalence among adults in 2014
was estimated to be 13%; with more cases in urban than
rural areas, this representing a decline from the 16%
prevalence reported in 2001 [6]. The prevalence of all
forms of tuberculosis for all ages in 2013–2014 in
Zambia was estimated to be 455/100,000 and bacterio-
logically confirmed TB among adults was 638/100,000
[7], underscoring the fact that Zambia has a high burden
of both TB and HIV.
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TB/HIV co-infection is one of the main drivers of poor
outcome for both diseases and has been widely studied
previously, including in Zambia [8, 9]. HIV infection has
been found to predict TB infection/disease [1] and TB
has been reported as a major cause of death among indi-
viduals with HIV [10–12]. Improving case detection of
TB/HIV co-infection has the potential to lead to early
treatment of both conditions and can impact positively
on treatment outcomes [13].
In view of this, there is a clear need to better under-
stand the HIV prevalence rate among TB patients and
determine the co-infection rate at a population level.
The Zambia national TB prevalence survey, the first to
offer HIV testing to all participants provided an excel-
lent opportunity to investigate this. This is the first study
to document the national level prevalence of TB/HIV in
a general population in Zambia.
Methods
This was a cross sectional survey of the HIV status of the
TB cases diagnosed during the national TB prevalence
survey implemented by the Ministry of Health in Zambia.
Nationwide data was collected among 66 clusters from
September 2013 to July 2014. The sampling frame was
nationwide clusters which were selected using random
sampling proportional to size, stratified by rural and urban
census supervisory areas (CSAs). The study participants
were aged 15 years and above residing in the area. Survey
participants were first screened for symptoms (chest pain
or fever or cough lasting 2 weeks or more) and subse-
quently a chest x-ray was performed regardless of the
screening result. Participants screening positive for
symptoms or having an abnormal chest x-ray submitted
a spot and morning sputum for mycobacterial (MTB)
investigation at any of the three central reference la-
boratories. The details of the enrolment, screening and
laboratory investigations are outlined elsewhere [7].
The TB cases were defined as cases having a positive
Mycobacterium tuberculosis (MTB) result by liquid cul-
ture and or by the XpertMTB/RIF assay regardless of
their TB treatment status at the time of the survey. The
detailed methods for bacteriological confirmation of TB
cases are outlined elsewhere [7]. Rapid HIV testing (with
tiebreakers) was performed on site on an opt-out basis
accompanied with pre and post-test counselling among
consenting individuals using the national algorithm. The
HIV testing procedure details were described earlier by
Chanda-Kapata et al. [14].
Data on HIV status, TB status and relevant socio-
demographic characteristics were extracted from the
main survey database for all detected TB cases. The
socio-demographic information collected included age, sex,
location, education level, marital status and socio-economic
status. The socio-economic status was measured using
wealth indices as described earlier [14]. The symptom and
chest x-ray screening outcome was also recorded; including
TB treatment history for both participants and household
members.
Data analysis was performed using STATA version 12.
The prevalence of HIV among the TB cases was esti-
mated as a proportion with 95% confidence limits. The
difference in outcomes for binary variables was estab-
lished using Pearson chi-square test while the Kruskall
Wallis difference in proportions was used for multiple
categorical variables.
Ethical considerations
The study protocol was cleared by the University of
Zambia Biomedical Research Ethics Committee (UNZAB-
REC) No: 020–08-12. Authorisation to conduct the survey
was sought in line with the existing national policies and
guidelines at national, provincial and district levels. The
Institutional Review Board (IRB) approved this consent
procedure. All the consent or assent forms were recorded
on standard forms which were developed for the study
and these were filed in lockable cabinets at the end of each
cluster operation and stored in central archives as per
national requirements.
Results
Overall, 46,099 individuals (84.1% of eligibles) participated
in the TB survey; 6708 (14.6%) were eligible for sputum
investigations and 265 (265/6123; 4.3%) bacteriologically
confirmed TB cases were identified. Out of the 265 MTB
cases, 151 (57.0%) agreed to be tested for HIV; 36 (23.8%;
95% CI 17.2–31.4) of whom were co-infected with HIV as
shown in Table 1. The mean age was 37.6 (range 24–70)
years. The proportion of individuals with TB/HIV co-
infection was significantly higher among the urban
(52.8%) versus rural (47.2%) residents (p = 0.001). There
were no significant differences in the prevalence of TB/
HIV co-infection by sex and education level. Participants
aged 35–44 years were found to have the highest preva-
lence of TB/HIV (50%; p = 0.0001) compared to other age
groups. More than two-thirds of the TB/HIV cases were
currently married (63.9%; p < 0.05) and 50.0% were from
the fourth wealth quintile (p < 0.05).
The majority of the TB/HIV cases were from Copperbelt
(n = 14; 39%) and Lusaka (n = 10; 28%) provinces respect-
ively; 4 (11%) from Western province and two each from
Eastern, Luapula and Southern respectively; one each
from Northern and North-Western and none from
Muchinga and Central provinces.
The ART status of the TB/HIV cases was not assessed
in this study.
The majority of the TB/HIV cases had a positive cul-
ture result (94.4%; p = 0.000) and were found to have an
abnormal chest x-ray (88.9%; p = 0.004) (Table 2). Also,
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half of the TB cases co-infected with HIV were smear
positive (p = 0.000) and 52.8% had a cough lasting more
than 2 weeks (p = 0.046). However, none of the 36
(100%) detected TB/HIV cases were on TB treatment at
the time of the survey while 5/36 (13.9%) reported a
previous history of TB treatment.
Table 3 highlights the signs, symptoms, imaging re-
sults, bacteriology and treatment status for TB cases
with and those without or unknown HIV co-infection as
observed in the Zambia national TB prevalence survey.
Smear positivity and culture positivity predicted TB/HIV
(p = 0.027 and p = 0.000) respectively. The HIV status
was unknown for 43% of the observed survey cases. The
signs, symptoms and bacteriology results among individ-
uals found with TB in the survey, but who declined to
be tested for HIV, were similar to those in whom an
HIV test was done.
Discussion
The prevalence of HIV among the TB cases tested in the
survey was up to five times lower than routinely reported
among clinical cases at facility level in the programmatic
setting, where co-infection rates of 60–62% are reported
[9, 15]. This implies that facility based data on co-infection
rates alone may not reflect the true epidemiological picture
of the general population. The difference is likely explained
by two processes. On the one hand, TB-HIV co-infected
patients are known to have poorer treatment outcomes [9]
and therefore TB/HIV co-infected patients who do not
seek care or cannot access care are likely to die early and
do not remain as prevalent cases in the community.
Furthermore, it is possible that TB/HIV co-infected indi-
viduals who fall sick are more likely to go to the health
facility earlier because of the severity of symptoms and are
thus potentially diagnosed earlier. It is also possible that
the cases detected in this survey were in the early stage of
disease since this was a TB screening of the general
(healthy) population. In addition, with an active TB screen-
ing program among PLHIV for TB like in Zambia, it can
be anticipated that those with known HIV are routinely
screened for TB during ARV visits and hence TB was
detected already and treated. Unfortunately in this survey
it was not assessed whether persons already knew their
HIV status or whether they were receiving ARV care. The
implication for TB/HIV detection and management in a
community setting require further investigation of the
costs and benefits.
The TB/HIV co-infection rate among those tested was
higher in the urban areas than in the rural settings; the
geographical areas in which the prevalence of TB was
Table 1 Sociodemographic characteristics of the TB/HIV cases
Variable N % (95% CI) P-value
Overall 36 23.8 (17.2–31.4)
Location
Rural 17 47.2 (30.4–64.5) 0.001b
Urban 19 52.8 (35.5–69.6)
Sex
Female 19 52.8 (35.5–69.6) 0.687b
Male 17 47.2 (30.4–64.5)
Age group
15–24 1 2.8 (0.0–14.5) 0.0001c
25–34 13 36.1 (20.8–53.8)
35–44 18 50.0 (32.9–67.1)
45–54 1 2.8 (0.0–14.5)
55–64 2 5.6 (0.7–18.7)
65+ 1 2.8 (0.0–14.5)
Education Level
None 2 5.6 (0.7–18.7) 0.187c
Primary 19 52.8 (35.5–69.6)
Secondary 13 36.0 (20.8–53.8)
Tertiary 2 5.6 (0.7–18.7)
Marital status
Never married 3 8.3 (1.8–22.5) 0.003c
Currently married 23 63.9 (46.2–79.2)
Divorced 9 25.0 (12.1–42.2)
Widowed 1 2.8 (0.0–14.5)
Wealth quintilea
Lowest 3 10.7 (2.3–28.2) 0.0001c
Second lowest 1 3.6 (0.1–18.3)
Middle 4 14.3 (4.0–32.7)
Fourth 14 50.0 (30.6–69.4)
Highest 6 21.4 (8.3–41.0)
aThe wealth quintile was unknown for 8 cases
bPearson chi square test
cKruskal-Wallis
Table 2 Signs and symptoms, imaging results, bacteriology and
treatment status among TB HIV con-infected cases as observed





Cough ≥2 weeks 19 (52.8) 0.046
Fever ≥2 weeks 7 (19.4) 0.844
Chest pain ≥2 weeks 17 (47.2) 0.411
Chest x-ray abnormality 32 (88.9) 0.004
Smear positive 18 (50.0) 0.000
Culture positive 34 (94.4) 0.000
Currently on TB treatment 0 (0.0) 0.987
Ever treated for TB 5 (13.9) 0.646
Household member ever treated for TB 3 (8.3) 0.489
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higher, were also found to have higher levels of TB/HIV
co-infections (as was the case for the highly urbanised
Copperbelt and Lusaka Provinces of Zambia). This was
similar to what has been reported from other countries
such as China [16], where TB patients from HIV preva-
lent areas also reported higher HIV rates. The TB/HIV
burden was also found to be higher within the age group
that is also mainly affected by TB [9]. It thus appears
that HIV may be a key driver of the TB epidemic in
Zambia. This shows that although good progress has been
made in implementing TB/HIV collaborative activities in
Zambia as reported by Kapata and colleagues [9] there is
need for sustaining effective coverage of interventions.
Notably, all the identified TB/HIV co-infected individ-
uals were not on TB treatment at the time of the survey,
similarly most (97%) of the TB cases without HIV were
not anti-TB treatment. It should be noted that all individ-
uals found with TB were included as cases irrespective of
their treatment status and mycobacterial load. This could
imply that these were HIV individuals in the early stage of
TB and therefore had not yet sought care. This is more so
as the screening procedures for the survey involved the
application of chest X-rays and more sensitive diagnostic
tools for diagnosis, namely culture methods and the Xpert
MBT/RIF assay. There is need for implementation re-
search to better understand the cost-effectiveness and
health benefits of detecting TB/HIV early in the general
population in resource constrained settings.
The majority of the identified TB/HIV cases had an ab-
normal chest x-ray while only 50% had a positive smear.
This may imply that chest x-ray screening of HIV infected
people for TB where possible may lead to increased TB
case detection [17]. The role of chest x-rays in routine
testing of people living with HIV should be explored fur-
ther as part of the diagnostic algorithm for TB screening.
TB programs should continue to routinely screen for
HIV in order to improve TB/HIV detection [18, 19]. On
the other hand, HIV treatment centres should in fact
scale up co-detection and co-management of TB as well
so that TB/HIV co-infected individuals can be provided
with comprehensive care and management [9]. Integra-
tion of TB/HIV diagnostic and treatment services in a
one stop shop approach is key regardless of whether a
patient entry into the health system is through the TB or
HIV clinic, because they have mutual goals to find and
treat cases [1, 9] however rigorous evaluation of the im-
pact of the various models of integration are required
[20]. Zambia should consider testing all presumptive TB
cases for HIV in a bid to implement a more sensitive
case detection algorithm.
The other important finding was that about a quarter
of the TB/HIV co-infected patients who were detected in
this study had a previous history of TB. The ART status
of the participants was not assessed in this study unfor-
tunately. However, it would be important to include
ART status in future population level prevalence surveys
so that the effect of ART on diseases duration could be
understood in this context. In clinical settings in
Zambia, TB/HIV collaborative activities have been im-
proving with the proportion of TB cases tested for HIV
rising from 23% in 2006, to 84% in 2010 but only 50% of
the TB/HIV cases were put on ART [9]. Understanding
the coverage of ART among TB/HIV cases can be useful
in identifying areas of potential intervention so that the
proportion of TB/HIV cases put on ART can be in-
creased. Ensuring that ARVs are readily available in TB
clinics may complement efforts to increase the number
of TB/HIV patients on ART and lead to improved treat-
ment outcomes of both diseases in the long term [21].
The national response to TB/HIV co-infection should
be designed to pay particular attention to high burden
areas when determining resource allocation. This will
ensure that adequate resources are allocated to cause sig-
nificant impact within reasonable time. Improving access
Table 3 Signs and symptoms, imaging results, bacteriology and treatment status for TB cases with and those without or unknown
HIV co-infection as observed in the Zambia national TB prevalence survey
Variable TB Cases with HIV
N (%)
TB Cases without HIV
N (%)




Number of cases 36 (13.6) 115 (43.4) 114 (43.0) 265 (100)
Cough ≥2 weeks 19 (52.8) 59 (51.3) 73 (64.0) 151 (57.0)
Fever ≥2 weeks 7 (19.4) 27 (23.5) 33 (28.9) 67 (25.3)
Chest pain ≥2 weeks 17 (47.2) 58 (50.4) 60 (52.6) 135 (50.9)
Chest x-ray abnormality 32 (88.9) 80 (43.5) 93 (81.6) 205 (77.4)
Smear positive 18 (50.0) 49 (42.6) 59 (51.7) 126 (47.5)
Culture positive 34 (94.4) 83 (72.2) 98 (86.0) 215 (81.1)
Currently on TB treatment 0 (0.0) 2 (1.7) 5 (4.4) 7 (2.6)
Ever treated for TB 5 (13.9) 13 (11.3) 17 (14.9) 35 (13.2)
Household member ever treated for TB 3 (8.3) 16 (13.9) 21 (18.4) 40 (15.1)
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to TB/HIV detection and management should be a pri-
ority on the national agenda; improvements in access to
TB care have potential to yield positive outcomes [21].
One area of focus for intensive case detection could be
the high-density urban areas where the prevalence of
both HIV and TB is high [7]. Intensified TB case find-
ing among people living with HIV is another area of
TB/HIV response which could be further strengthened
as a matter of priority.
The main limitation of this analysis is the high HIV
testing refusal rate which could have introduced selec-
tion bias thereby affecting the precision of the reported
estimates. The proportion of TB survey participants
refusing HIV testing was 31.6% [14]; this potentially
overestimated or underestimated the HIV-TB burden
reported in this study depending on the characteristics
of those who declined testing. If all decliners were HIV
negative the prevalence would have been 14% (36/265)
and if all were HIV positive, the prevalence would have
been 57% (150/265). . Since the HIV testing refusal rates
were higher among the younger survey participants,
rural residents and the married [14] some bias may have
been introduced in particular for these subgroups.
Nonetheless, it remains key to address non acceptance
of HIV testing in future surveys in order improve esti-
mates and enhance appropriate care provision. Addition-
ally, the survey was designed to detect pulmonary TB
only hence there is a possibility of the occurrence of
extra-pulmonary TB/HIV (EPTB/HIV), which was not
investigated. This may have underestimated the true
burden of TB/HIV in the general population, more so
that HIV individuals tend to have EPTB as seen from a
Zambian study [22] and routine surveillance data [23].
The use of FASH screening for extra-pulmonary TB
(EPTB) detection may be considered in future surveys;
FASH screening has been shown to detect EPTB in rural
settings in Africa [24].
It is possible to use tuberculosis prevalence surveys to
estimate the burden and characteristics of HIV among
pulmonary TB patients specifically and in the general
population. However, there is need for better yields in
terms of the proportion of TB survey participants
accepting an HIV test in order to reduce selection bias.
Conclusions
The TB/HIV prevalence in the general population was
found to be about five times lower than routinely reported
among incident cases at facility level. TB/HIV co-infection
rate was higher in areas with higher TB prevalence. Seeing
that all TB/HIV co-infected individuals were not on anti-
TB treatment; it is important to investigate innovative
effective strategies for ensuring early case detection and
treatment for these individuals. However, the costs and
benefits of early detection and treatment of TB and HIV
in a general population require further investigation in
operational settings. Ensuring high acceptance of HIV
testing in a community survey setting is key to improve
estimates of TB/HIV co-infection.
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